R Squared’s Pacific Biosciences PACB Stock Holding History

R Squared’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-6,140	Closed	-$11.2K	–	1137
2024 Q4	$11.2K	Buy	+6,140	New	+$12K	0.01%	1106

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return

EDRH

Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

R Squared's PACB Position: Q1 2025 in Review

R Squared sold out of Pacific Biosciences (PACB) in Q1 2025, closing a stake of 6,140 shares — an estimated $11.2K sold.

R Squared first reported a position in PACB in Q4 2024 and held it in 1 quarter. The position peaked at $11.2K in Q4 2024. 225 funds tracked by Wall St. Rank hold PACB as of Q1 2025.

R Squared reported no remaining Pacific Biosciences position as of Q1 2025 after selling out during the quarter.
R Squared sold 6,140 Pacific Biosciences shares in Q1 2025, an estimated $11.2K.
R Squared first reported a position in Pacific Biosciences in Q4 2024 and held it in 1 quarter.
R Squared's Pacific Biosciences position peaked at $11.2K in Q4 2024.
225 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.